Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HER2-amplified colorectal cancer, drawn from the whole corpus: 10 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No randomised evidence yet for HER2 blockade in first line.
RAS co-mutation blunts dual HER2 blockade and the best option for those patients is unclear.
Optimal sequence of tucatinib-trastuzumab and trastuzumab deruxtecan is untested.
HER2 mutations without amplification have no proven therapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
ORR 37.
A milestone in how this cancer is treated.
Phase 2 ORR 38.
A milestone in how this cancer is treated.